Trial Profile
A clinical proof of concept study (POC) with cannabidiol (CBD) and Gabapentin chewing gum product to treat patients with restless leg syndrome (RLS)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Cannabinoid receptor modulators (Primary)
- Indications Restless legs syndrome
- Focus Proof of concept; Therapeutic Use
- 22 Jul 2017 New trial record